

亞東紀念醫院

Ovarian Cancer

化學治療處方集

2014-05 制定

Ovarian Cancer 化學治療處方參考集

2014-05 制定

【Carboplatin + Paclitaxel】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Carboplatin (AUC = 5~7.5) in N/S 250mL, IV drip over 1 hour on day 1

Paclitaxel 175 mg/m² over 3 hours day 1

Every 21 days * 6 cycles

For ovarian cancer patients

References:

1. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194-200.

【Dose-dense Paclitaxel + Carboplatin】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Carboplatin (AUC = 6) in N/S 250mL IV drip over 1 hour on day 1

Paclitaxel 80 mg/m² IV drip over 1 hour on day 1, 8, 15

Every 21 days * 6 cycles

For ovarian cancer patients

References:

1. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:1331-8.
2. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-6.

Ovarian Cancer 化學治療處方參考集

2014-05 制定

【Cisplatin + Cyclophosphamide】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Cisplatin 75mg/m² on day 1

Cyclophosphamide 750mg/m² on day 1

Every 21 days

For ovarian cancer patients

References:

1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.

【Carboplatin + Docetaxel】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Docetaxel 60-75 mg/m² in N/S 250mL IV drip over 1 hour on day 1

Carboplatin (AUC = 5 or 6) in N/S 250mL IV drip over 1 hour on day 1

Every 21 days * 6 cycles

For ovarian cancer patients

References:

1. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91.

Ovarian Cancer 化學治療處方參考集

2014-05 制定

【IP Cisplatin + Paclitaxel】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Paclitaxel 135 mg/m² IV drip over 3 or 24 hours on day 1

Cisplatin 75-100 mg/m² IP on day 2 after IV Paclitaxel

Paclitaxel 60 mg/m² IP on day 8

Every 21 days * 6 cycles

For ovarian cancer patients

References :

1. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.

【Weekly Topotecan】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Topotecan 4 mg/m² in N/S 250mL, IV drip over 30 minutes, on days 1, 8, and 15

Every 28 days

References :

1. Sehouli J, Stengel D, Harter P, et al. Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol 2011;29:242-8.

Ovarian Cancer 化學治療處方參考集

2014-05 制定

【Bevacizumab-containing Regimens (ICON 7 and GOG 218)】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Paclitaxel 175 mg/m² IV drip over 3 hours on day 1

Carboplatin AUC = 5-6 IV drip over 1 hour on day 1

Bevacizumab 7.5 mg/kg IV drip over 30-90 minutes on day 1

Every 21 days * 5-6 cycles

Continue Bevacizumab(健保不給付) for up to additional 12 cycles

OR

Paclitaxel 175 mg/m² IV drip over 3 hours on day 1

Carboplatin AUC = 6 IV drip over 1 hour on day 1

Every 21 days * 6 cycles

Starting from day 1 of cycle 2, Bevacizumab(健保不給付)15 mg/kg IV drip over 30-90 minutes

Every 21 days * 22 cycles

For ovarian cancer patients

References :

1. Stark D, Nankivell M, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. *Lancet Oncol* 2013;14:236-43.
2. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med* 2011;365:2484-96.
3. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. *N Engl J Med* 2011;365:2473-83.

【Paclitaxel + Ifosfamide】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Paclitaxel 135mg/m² on day 1

Ovarian Cancer 化學治療處方參考集

2014-05 制定

Ifosfamide 1.6 gm/m² on day1-3

Every 21 days

For advanced ovarian cancer patients, especially for carcinosarcoma of ovary.

References :

1. Miglietta L, Amoroso D, Bruzzone M, et al. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study. *Oncology* 1997;54:102-7.
2. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. *J Clin Oncol* 2007;25:526-31.

【Bleomycin + Etoposide + Cisplatin (BEP)】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Bleomycin 15mg/m² on day 1, 2 and 3 (maximum 25mg per day)

Etoposide 100mg/m² IV drip day 1, 2 and 3

Cisplatin 100mg/m² IV on day 1

Every 21 days * 3-4 cycles

For ovarian cancer (germ cell tumor & sex cord stromal tumor) patients

References :

1. Dimopoulos MA, Papadimitriou C, Hamilos G, et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. *Gynecol Oncol* 2004;95:695-700.

【Carboplatin + liposomal doxorubicin】

- 化療屬性：
- Induction / neoadjuvant
 - Concurrent chemoradiotherapy (CCRT)
 - Palliative
 - Adjuvant

Liposomal doxorubicin 40 mg/m², diluted in 250 ml of 5% D5W iv drip over 1 hour.

Carboplatin (AUC = 5 or 6) iv drip over 30 min

Ovarian Cancer 化學治療處方參考集

2014-05 制定

For recurrent ovarian cancer patients

References :

1. Hsiao SM, Chen CA, Lin HH, et al. Phase II trial of carboplatin and distearoylphosphatidylcholine pegylated liposomal doxorubicin (Lipo-Dox) in recurrent platinum-sensitive ovarian cancer following front-line therapy with paclitaxel and platinum. *Gynecol Oncol* 2009;112:35-9.
2. Taiwanese Gynecologic Oncology Group, Chou HH, Wang KL, et al. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. *Gynecol Oncol* 2006;101:423-8.